Intellia Therapeutics (NTLA) announced it has completed enrollment in the global Phase 3 HAELO study of lonvoguran ziclumeran, Ionov-z, for the treatment of hereditary angioedema. Topline data are expected in the first half of 2026. Intellia is on track to submit a biologics license application in the second half of 2026 to support the company’s plans for a U.S. launch in the first half of 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cathie Wood Bets on AMD, Bullish, and Figma; Trims Tempus AI, Roku
- Cathie Wood’s ARK Investment buys 615.8K shares of Intellia Therapeutics today
- Cathie Wood Buys the Dip in Figma Stock, Sells Roku and Genius Sports
- Cathie Wood’s ARK Investment buys 131.7K shares of Intellia Therapeutics today
- CRSP, NTLA: Cathie Wood Adds to Biotech Favorites amid Buying Spree, Cuts Roku Stake